Patrick Mauro Investment Advisor INC. cut its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 9.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,194 shares of the company’s stock after selling 2,848 shares during the quarter. AbbVie comprises 2.4% of Patrick Mauro Investment Advisor INC.’s holdings, making the stock its 9th biggest position. Patrick Mauro Investment Advisor INC.’s holdings in AbbVie were worth $7,425,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Fisher Asset Management LLC increased its stake in shares of AbbVie by 252.6% in the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. Corient Private Wealth LP bought a new stake in shares of AbbVie during the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new stake in shares of AbbVie during the second quarter valued at approximately $2,905,952,000. Jupiter Topco LLC acquired a new position in shares of AbbVie during the second quarter worth approximately $1,560,354,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of AbbVie during the second quarter worth approximately $817,473,000. 70.23% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.
AbbVie Trading Up 0.1%
ABBV stock opened at $295.18 on Monday. The firm’s 50-day moving average is $275.51 and its two-hundred day moving average is $240.91. The company has a market capitalization of $521.77 billion, a price-to-earnings ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $1.86 earnings per share. On average, equities research analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a $1.82 dividend. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. AbbVie’s payout ratio is currently 119.10%.
Analysts Set New Price Targets
Several analysts recently commented on ABBV shares. UBS Group raised their target price on AbbVie from $275.00 to $295.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Scotiabank lifted their target price on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and boosted their price target for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. Guggenheim increased their price target on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a research note on Monday, November 2nd. Finally, Canaccord Genuity Group raised their price target on AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $297.46.
Read Our Latest Research Report on ABBV
AbbVie Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Recommended Stories
- Five stocks we like better than AbbVie
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
